Covid19
Conditions
Keywords
Aviptadil, Inhaled, COVID-19, Pandemic
Brief summary
This study is a multicenter, prospective, placebo-controlled, comparative, randomized, double-blind local phase II clinical trial. Duration of study is 18 months. In the study, patients will be randomized in a ratio of 1: 1 into two arms, standard medical therapy + placebo versus standard medical therapy + inhaled Aviptadil arms. Randomization will be carried out by the block randomization method. In the event that patients need intensive care in the study, the patients will be taken into intensive care unit and excluded from the study and their treatment will be continued in the intensive care unit as deemed appropriate by the physician and it is foreseen that inhaled Aviptadil will be used for a period of minimum 7 and maximum 14 days. Aviptadil will be discontinued in patients who do not heal after 14 days. This study includes 8 visits, consisting of a total of 7 physical visits and 1 phone follow-up visit. The study period will be 6 months for each patient. Patient recruitment is planned to take 12 months. Study centers will be asked to use investigational products for their patients who sign the informed consent form for 12 months. The study population will consist of patients 18 years of age and older with COVID-19 pulmonary involvement and hospitalized patients.
Interventions
DRUGInhaled Aviptadil
Aviptadil is the synthetic analogue of the Vasoactive Intestinal Peptide (VIP), a biologically active 28 amino acid natural peptide that is endogenously synthesized in humans. It is one of the signaling molecules of the neuroendocrine immune network and has vasodilator, anti-proliferative, anti-inflammatory and immunomodulatory properties.
DRUGPlacebo
Aviptadil Placebo will be used for this arm.
Sponsors
Centurion Pharma
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
Double-blind
Intervention model description
In the study, patients will be randomized in a ratio of 1: 1 into two arms, standard medical therapy + placebo versus standard medical therapy + inhaled Aviptadil arms. Randomization will be carried out by the block randomization method.
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1.18 years and older women or men, under 70 years old 2.Patients with positive SARS-CoV-2 real time PCR result and an appearance in line with COVID-19 pneumonia on thorax CT 3\. Need for oxygen support or SpO2 \<94 in room air 4\. Patients who can use a nebulizer (with assistance when necessary) 5.Patients who are willing and capable (mentally and physically) who can sign a written informed consent form, to participate in all aspects of the study, to participate in the planned visits and to comply with the terms of the protocol.
Exclusion criteria
1. Intensive care admission 2. The need for mechanical ventilation 3. Patients with previously known organ (kidney, heart and liver) failure \* To be determined as previously known heart failure (EF \<30), previously known liver failure (Child-Pugh C) and previously known renal failure (Cr.clerance \<30). 4. COVID-19 disease with no indication for hospitalization 5. Participants in another clinical trial 6. Pregnancy or lactation 7. Solid organ or stem cell transplantation story 8. Patients with collagen tissue disease 9. Use of immunosuppressive therapy 10. Procalcitonin ≥2 (baseline visit) 11. Under 18 years old 12. Those who had myocardial infarction in the last 3 months 13. Those who do not have the capacity to understand the possible results, scope and nature of the study due to legal insufficiency and / or other reasons. 14. Those who, in the opinion of the investigator, cannot continue the treatment protocol regularly or cannot cooperate 15. Presence of malignancy 16. Patients with neurological diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical improvement | 6 months | Being discharged within 30 days of starting treatment, no need for oxygen support |
Secondary
| Measure | Time frame |
|---|---|
| The rate of patients entering intensive care | 6 months |
| Patients' rate of needing mechanical ventilation | 6 months |
| Change in SpO2 (measured by pulse oximetry) | 6 months |
| Normalization in body temperature | 14 days |
| Dyspnea Scale (Modified Borg Dyspnea Scale (MBS) | 6 months |
| 6-minute walking test | 28 days |
| The time it takes for patients to improvement of their symptoms (cough, shortness of breath) | 6 months |
| The time it takes for the PCR to become negative | 14 days |
| Time to discharge of patients | 6 months |
| Need for re-hospitalization | 6 months |
| Normalization in laboratory results of blood parameters (PT, aPTT, D-dimer, Ferritin, Lymphocyte Count, CRP) | 28 days |
| Normalization in laboratory results of biochemistry parameters (Glucose, ALT, AST, LDH, Total Bilirubin, Total Protein, Albumin, Alkaline Phosphatase, GGT, Sodium, Potassium, Calcium, Phosphor, CPK, Magnesium, eGFR, BUN, Uric Acid, Creatinine Clearance) | 28 days |
| Mortality rate | 6 months |
| Normalization in Blood Pressure | 14 days |
| Normalization in Respiration Rate/Minute | 14 days |
| Normalization in SpO2 | 14 days |
| Sequelae and recovery rates in control thorax computed tomography at the end of month 1 and 6 months | 6 months |
Countries
Turkey (Türkiye)
Outcome results
None listed